Immutep reported encouraging survival results in a sarcoma study and won U.S. patent protection through 2038. A separate lung-cancer trial ended early, but the new study and patent support a positive read.
The survival findings may help Immutep move efti toward larger studies, and the patent protects some efti combinations for years. The survival data are preliminary: only 38 patients were counted, and follow-up continues. A separate lung-cancer study ended early, a serious setback. The sarcoma results and patent still support a positive read, though later studies must confirm the benefit.
Merck's Keytruda was part of the sarcoma treatment mix, but the study reports results for the combination, not a separate benefit for Merck. It gives no clear reason to change Merck's outlook.
Follow Immutep Limited (IMMP) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for IMMP